Novel Inflammatory Markers in Different Phenotypes of Severe Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2023-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Asthma is a highly prevalent chronic airway inflammatory disease characterized by airway hyper-responsiveness, reversible airflow obstruction and increased mucus secretion, involving large and small airways. An emerging sub-phenotype of severe asthma is the late onset disease associated with nasal polyposis, a frequent co-morbidity that significantly impacts lung function and symptom control. On the basis of the infiltrate found in the sputum, asthma can be divided into four distinct phenotypes: eosinophilic, neutrophilic, mixed granulocytic and pauci-granulocytic. The majority of patients with eosinophilic asthma are sensitive to corticosteroids, and biological therapies targeting eosinophils (anti-Interleukin (IL)-5 and anti-IL5R) have been recently approved. However, it is known that some asthmatics, particularly those who have severe disease and are resistant to corticosteroids, have elevated neutrophil counts in the airway where they play a vital role in the exacerbation of the disease. However, the precise role of neutrophils in severe asthma and the mechanisms involved in neutrophil-induced tissue damage have not been clarified yet.

The hypothesis of the study is that neutrophils and eosinophils can contribute to the severity of asthma by changing their phenotypes according to the airway environment. Thus, a better understanding of the roles of neutrophils and eosinophils in severe asthma may lead to the identification of novel biomarkers and the development of new therapeutic approaches in different phenotypes of severe asthma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Value of FeNO in Predicting Airway Eosinophilic Inflammation

NCT04885738

Biomarkers Airway Inflammation

UNKNOWN

Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program

NCT02103348

Asthma

COMPLETED

Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers

NCT02660853

Asthma

COMPLETED NA

E-nose and Inflammatory Asthma Phenotypes

NCT02026336

Persistent Asthma

COMPLETED NA

Pilot Study for the Application of Low Power External Bioelectronic Devices in the Diagnosis of Bronchial Asthma.

NCT06836375

Asthma Bronchiale

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma Nasal Polyps

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

asthma with nasal polyps

severe asthma with involvement of the upper airways (chronic rhinosinusitis with nasal polyps)

observational

Intervention Type OTHER

observation of biomarkers in different asthma groups

severe asthma without nasal polyps

severe asthma without involvement of the upper airways

observational

Intervention Type OTHER

observation of biomarkers in different asthma groups

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

observational

observation of biomarkers in different asthma groups

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female
* age (18-65 years)
* Diagnosis of severe asthma according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) definition, with and without nasal symptoms
* normal pulmonary function post-therapy (FEV1 post-bronchodilation: greater than 80% of the predicted value, with FEV1/ vital capacity (VC) \> 88-89% - for males and females, respectively - of the predicted value)
* non reversible chronic airflow limitation (FEV1 post-bronchodilation: lower than 70% of the predicted value, with FEV1/VC \< 88-89% of the predicted value)
* Signing of the informed consent

Exclusion Criteria

* Referred Pregnancy
* Use of therapy with beta-blockers
* Smoking (current or within the previous 3 months)
* Negation to participate to the study
* Current upper and lower airways infectious diseases
* Current systemic infectious diseases

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No